| 6.38 -0.08 (-1.24%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.43 | 1-year : | 9.84 |
| Resists | First : | 7.21 | Second : | 8.43 |
| Pivot price | 6.16  |
|||
| Supports | First : | 5.57 | Second : | 4.56 |
| MAs | MA(5) : | 6.4 |
MA(20) : | 6.24 |
| MA(100) : | 5.73 |
MA(250) : | 5.36 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.1 |
D(3) : | 69.8 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 11.88 | Low : | 1.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CCCC ] has closed below upper band by 33.8%. Bollinger Bands are 18.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.71 - 6.74 | 6.74 - 6.77 |
| Low: | 6.1 - 6.13 | 6.13 - 6.16 |
| Close: | 6.33 - 6.38 | 6.38 - 6.43 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Tue, 17 Sep 2024
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest - MarketBeat
Wed, 11 Sep 2024
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Tue, 10 Sep 2024
C4 Therapeutics earns $8 million from Biogen alliance - Investing.com
Tue, 10 Sep 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen - StockTitan
Sun, 08 Sep 2024
CCCC - C4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tue, 03 Sep 2024
C4 Therapeutics appoints new board member - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 88.4 (%) |
| Shares Short | 11,630 (K) |
| Shares Short P.Month | 10,470 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.58 |
| Profit Margin | 0 % |
| Operating Margin | -178.6 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -44.9 % |
| Qtrly Rev. Growth | 350.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.42 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -3.36 |
| PEG Ratio | -0.2 |
| Price to Book value | 1.77 |
| Price to Sales | 15.05 |
| Price to Cash Flow | -5.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|